Diagnostyka company profile
Company profile
Diagnostyka has 8,645 employees and is headquartered in Kraków, Poland.
Based in Kraków, Diagnostyka S.A. has been active since 1998 as a medical laboratory serving clients across Poland. Its offer combines imaging procedures, namely magnetic resonance imaging, computed tomography, X-ray and ultrasound, with specialised laboratory research in microbiology, autoimmunity, toxicology and molecular biology. The company also carries out human genome research, histopathological and cytological examinations, immunohistochemical tests and cytogenetic tests. Its customers are individual clients as well as public and private entities. Its activities are concentrated in Poland.
In the fiscal year ended 31 December 2025, revenue reached 2.4 billion PLN, an increase of 23.6% on the prior year, and net profit came to 251.6 million PLN. The company has 8,645 employees and its headquarters are in Kraków, where it was founded in 1998.
Company facts
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- Poland
- Headquarters
- Ul. Prof. Michala Zyczkowskiego 16, 31-864, Kraków
- Employees
- 8,645
- Chief executive
- Jakub Swadzba
- Founded
- 1998
- Fiscal year
- January - December
- Listing
- DIA · GPW
- Currency
- PLN
- ISIN
- PLDGNST00012
- Website
- diag.pl
Diagnostyka and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| DiagnostykaDIA | Poland | $1.27B | 8,645 | 14.9% | 20.2 |
| DiaSorinDIA | Italy | $4.21B | 3,212 | 22.3% | 28.6 |
| QiagenQIA | Germany | $10.23B | 5,400 | 26.7% | 28.5 |
| bioMérieuxBIM | France | $11.82B | 14,562 | 16.0% | 23.4 |
| Eurofins ScientificERF | France | $16.03B | 65,000 | 14.1% | 29.6 |
| Lonza GroupLONN | Switzerland | $54.2B | 20,141 | 23.5% | 43.2 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.